Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production

Sourcebusiness wire
Date Published04/26/2023
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Bristol Myers Squibb
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2023
Year reshoring implemented or to be implemented:2023
Domestically, the work will be done:In-house
City reshored to:Libertyville
State(s) reshored to:IL
If relevant, work nearshored to:-
Product(s) reshoredCAR T cell therapies
Find Reshoring Articles